Journal of Population Therapeutics & Clinical Pharmacology

REVIEW ARTICLE
DOI: 10.53555/86evc894

"ADVANCEMENTS IN ANALYTICAL METHODOLOGIES FOR THE DETERMINATION OF BUMETANIDE IN COMBINED DOSAGE FORMS"

Dhrumi Y Patel[1], Dr. Neha Tiwari[2*], Dr. Pragnesh Patani[3]

[1]Department of Pharmaceutical Quality Assurance, Khyati College of Pharmacy, Ahmedabad, Gujarat, India.
[2*]Department of Pharmaceutical Chemistry, Khyati College of Pharmacy, Ahmedabad, Gujarat, India.
[3]Department of Pharmacology, Khyati College of Pharmacy, Ahmedabad, Gujarat, India.

***Corresponding Author:** Dr. Neha Tiwari
*Khyati College of Pharmacy, Ahmedabad, Gujarat. **Email ID:** tiwarin1707@gmail.com

ABSTRACT: Bumetanide, a potent loop diuretic, is used in managing edema in congestive heart failure, renal impairment, and hepatic cirhosis. It has also been linked to neurological disorders, increasing the need for reliable analytical methods. Accurate determination of Bumetanide in combined dosage forms is crucial for quality, safety, and efficacy. Challenges include matrix complexity, interference from co-formulated drugs, and stability issues. Advancements in analytical methodologies have improved resolution, accuracy, and faster analysis. Hyphenated techniques like LC-MS/MS have enhanced sensitivity and specificity. Green analytical approaches and Quality by Design principles promote eco-friendly practices. Future perspectives emphasize the need for innovative, automated, and environmentally conscious methodologies for bumetanide determination in combined dosage forms.

KEYWORDS: Bumetanide, Furosemide, Loop diuretics, Analytical Methods (HPLC, LC-MS/MS), Combined Dosage-Form

INTRODUCTION: Bumetanide is a powerful novel diuretic that differs from existing diuretics in its structural makeup. Bumetanide, a derivative of metanilamide, differs from Frusemide and the thiazides, which are derived from sulphanilamide in that it contains the additional significant distinction caused by the presence of a phenoxy group.[1]

Bumetanide is part of the sulfonamide class. It is clinically suggested to treat edema related to hepatic cirrhosis, renal impairment, and congestive heart failure. It is also used to treat hypertension. Inhibiting the $Na^+/K^+/2Cl^-$ symporter in the thick ascending limb of the loop of Henle is its main mechanism of action. This leads to greater excretion of water, sodium, and chloride, which lowers blood pressure and extracellular fluid volume.[2]

On a weight basis, Bumetanide has around 40 times the pharmacological potency of Furosemide.[3]



FIGURE 1: Mechanism of Bumetanide

DRUG PROFILE OF BUMETANIDE:



FIGURE 2: chemical structure of Bumetanide

TABLE 1: Drug profile of Bumetanide [4]

IUPAC Name	3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
Chemical Formula	$C_{17}H_{20}N_2O_5S$
Molecular Mass	364.4 g/mol
Physical State	Solid
Solubility	Soluble in ethanol, acetone, water
Therapeutic Use	To help treat fluid retention, liver disease, kidney disease.
pKa	Acidic:3.6 Basic:7.7
Chemical Class	sulfamoyl benzoic acid derivatives

MECHANISM OF ACTION OF FUROSEMIDE:

Acting on the thick ascending loop of Henle, Furosemide inhibits the NKCC2 co-transporter, which decreases reabsorption of sodium, chloride, and potassium. This causes a significant increase in urine output and reduced fluid retention. Discovered in the late 1950s and used clinically since the 1960s, it serves as an essential medication for edema and hypertension treatment.[5]



FIGURE 3: Chemical Structure of Furosemide

TABLE 2: Drug Profile of Furosemide [6]

IUPAC Name	4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
Chemical Formula	$C_{12}H_{11}ClN_2O_5S$
Molecular Mass	330.74 g/mol
Physical State	Solid
Solubility	Soluble in water
Therapeutic Use	To treat hypertension, heart failure.
pKa	Acidic:3.8 Basic:9.8
Chemical Class	Anthranilic acid derivatives.

DEVELOPMENT OF BUMETANIDE:

Bumetanide, a highly effective "high-ceiling" loop diuretic, was introduced in the late 1960s after systematic evaluation of more than 5,000 derivatives of 3-amino-5-sulfamoylbenzoic acid, with the goal of creating agents with greater potency and consistency than Furosemide. [7,8] Its activity was found to rely heavily on the incorporation of a sulfamoyl group, a phenoxy substituent, and a butylamino side chain.[9]

By the early 1970s, clinical research confirmed its therapeutic value in treating edema linked to cardiac, hepatic, and renal conditions, revealing that bumetanide is about forty times stronger than Furosemide by weight, yet retains a similar pharmacokinetic behavior.[10,11] At the mechanistic level, it exerts its effect by blocking the Na^+-K^+-$2Cl^-$ cotransporter (NKCC2) located in the thick ascending limb of Henle's loop, which results in substantial natriuresis and diuresis.[12] Beyond its established role, more recent investigations suggest potential in neurology, where it can influence neuronal chloride regulation through inhibition of NKCC1. [13,14]

Therefore, Bumetanide stands as both a landmark achievement in loop diuretic therapy and an agent of emerging clinical relevance.

PHARMACOTHERAPEUTIC GROUP OF BUMETANIDE:

Bumetanide is a member of the loop diuretic group, also known as "high-ceiling diuretics," which are chemically derived from sulfonamides. Its pharmacological action takes place in the thick ascending limb of Henle's loop, where it inhibits the Na^+-K^+-$2Cl^-$ cotransporter (NKCC2). This blockade results in strong elimination of sodium, chloride, potassium, and water, producing marked diuretic and natriuretic effects.

Clinically, loop diuretics such as Bumetanide are important in managing fluid overload, particularly in conditions like congestive heart failure, hepatic cirrhosis, renal insufficiency, and acute pulmonary edema, where rapid fluid removal is often life-saving.[15]

PHARMACODYNAMIC EFFECT OF BUMETANIDE:

Bumetanide works by blocking the Na^+-K^+-$2Cl^-$ cotransporter (NKCC2) in the thick ascending limb of Henle's loop, preventing sodium, potassium, and chloride reabsorption. This causes strong natriuresis and diuresis, since 20–25% of filtered sodium is normally reabsorbed here. It also

increases calcium and magnesium loss, reduces the kidney's concentrating ability, and stimulates renin release. Clinically, it rapidly decreases extracellular fluid and relieves edema, being about 40 times more potent than furosemide by weight.[16]

PHARMACOKINETIC OF BUMETANIDE:

1. **Absorption:** After oral administration, Bumetanide is quickly and efficiently absorbed, with a bioavailability generally greater than 80%. Maximum plasma levels are usually observed within 30 to 60 minutes of dosing.[17]
2. **Distribution:** Bumetanide shows a moderate level of distribution within body tissues after administration. A significant proportion of the drug, about 95%, binds strongly to plasma proteins, mainly albumin. This high degree of protein binding plays an important role in determining its therapeutic effectiveness and also influences the likelihood of interactions with other medications that compete for binding sites.[18]
3. **Metabolism:** Following administration, Bumetanide distributes to body tissues to a moderate extent. Approximately 95% of the drug remains bound to plasma proteins, particularly albumin. This extensive protein binding is a key factor in modulating its pharmacological activity and may also increase the possibility of interactions with other drugs that utilize the same binding sites.[19]
4. **Excretion**: The primary route of elimination for Bumetanide is through the kidneys, where the drug is excreted both in its unchanged form as well as in the form of metabolites. Its elimination half-life is relatively short, averaging between 1 and 1.5 hours, which explains the brief duration of its diuretic action and the need for repeated dosing in certain therapeutic situations.[20]

Importance of Maintaining Heart Failure Control

Maintaining optimal control of heart failure (HF) is critical for reducing morbidity, mortality, and healthcare costs associated with this chronic condition. Effective management helps prevent disease progression, minimizes episodes of acute decompensation, and reduces hospitalizations, which are common in patients with poorly controlled HF.

Proper control of fluid balance, blood pressure, and cardiac workload through medications such as diuretics, ACE inhibitors, beta-blockers, and lifestyle interventions improves functional capacity and quality of life. Additionally, maintaining stable hemodynamics and preventing excessive fluid retention reduces the risk of complications such as pulmonary edema, arrhythmias, and renal dysfunction. Continuous monitoring, adherence to therapy, and timely adjustment of medications are therefore essential to achieve long-term clinical stability and to improve survival outcomes in patients with heart failure. [21,22]

ANALYTICAL METHOD:

Bumetanide, a strong loop diuretic, is analyzed in pharmaceutical products and biological samples using various analytical techniques to ensure proper dosing, quality assurance, and pharmacokinetic studies. UV-Visible spectrophotometry and its derivative methods are popular due to their simplicity and cost-effectiveness, typically measuring absorbance near 233–234 nm. High-performance liquid chromatography (HPLC), frequently employing C18 reverse-phase columns with methanol–water or acetonitrile–water mobile phases, is widely used for precise, sensitive, and specific quantification in tablets, injectable forms, plasma, and urine samples. Other methods include thin-layer chromatography (TLC) for qualitative or semi-quantitative assays, liquid chromatography–mass spectrometry (LC-MS) for detecting trace amounts in biological samples, and electroanalytical techniques like potentiometry and voltammetry for quick assays with low detection limits. Official pharmacopeias such as the USP and BP endorse HPLC or UV spectrophotometry for routine quality control of bumetanide in pharmaceutical formulations. [23]

REPORTED METHODS OF ESTIMATION OF BUMETANIDE:

TABLE 3: Reported methods of estimation of Bumetanide

Sr. No.	Drug	Method	Detection mode	Description	References No
1	Bumetanide	HPLC	328nm	Solvent: Methanol: Water (75%:25%v/v) Linearity range: 0.208-1.040 µg/ml	[24]
2	Bumetanide	HPLC	220nm	Solvent: Methanol: Water (60%:40%v/v) Linearity range: 0.013-1.040µg/ml	[25]
3	Bumetanide	LC-MS	-	Solvent: Acetonitrile: Water (50%:50%v/v) Linearity range: 0.3-1µg/ml	[26]
4	Bumetanide	LC-MS	-	Solvent: 1% Acetic acid in water: acetonitrile Linearity range: 1-500µg/ml	[27]
5	Bumetanide	HPLC	254nm	Solvent: Glacial acetic acid: Tetrahydrofuran: Water: methanol (2:5:45:50) Linearity range: -	[28]

REPORTED METHODS OF ESTIMATION OF FUROSEMIDE:

TABLE 4: Reported methods of estimation of Furosemide

Sr. No.	Drug	Method	Detection mode	Description	References No
1	Furosemide	HPLC	272nm	Mobile Phase: Glacial acetic acid and acetonitrile (50:50%v/v) Flow Rate: 1.0mL/min Retention time: 7.03minutes Linearity: 10-120 µg/ml	[29]

OFFICIAL METHODS OF ESTIMATION OF FUROSEMIDE:

TABLE 5: Official methods of estimation of Furosemide

Sr. No.	Drug	Method	Detection mode	Description	References No
1	Furosemide [IP, BP, Ph. Eur., USP]	HPLC	271nm	Stationary Phase: Octadecylsilyl Silica Gel C_{18} Mobile Phase: Methanol: Phosphate buffer (35:65%v/v) Flow Rate: 1.0mL/min Injection Volume: ~20µL	[30,31,32,33]

CONCLUSION:

The advancements in analytical methodologies for the determination of Bumetanide in combined dosage forms highlight the transition from conventional spectrophotometric techniques to highly sophisticated methods such as HPLC, LC–MS. These modern approaches offer superior sensitivity, selectivity, and reproducibility, addressing the analytical challenges posed by multi-component formulations and complex biological matrices. Their application ensures accurate quality control, regulatory compliance, and reliable pharmacokinetic evaluation, which are essential for therapeutic efficacy and patient safety. Overall, these innovations not only strengthen the analytical framework for Bumetanide but also support the development of novel fixed-dose combinations and contribute to the advancement of pharmaceutical research and clinical practice.

REFERENCES:

1. Asbury MJ, Gatenby PB, O'sullivan S, Bourke E. Bumetanide: potent new “loop” diuretic. *Br Med J*. **1972** Jan 22;1(5794):211-3.
2. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. *Annals of internal medicine*. **1991** May 15;114(10):886-94.
3. Brater DC. Clinical pharmacology of loop diuretics. Drugs. **1991** Jun;41(Suppl 3):14-22.
4. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 2471, Bumetanide; **2025** Sept. 12.
5. Huang X, Dorhout Mees E, Vos P, Hamza S, Braam B. Everything we always wanted to know about furosemide but were afraid to ask. *American Journal of Physiology-Renal Physiology*. **2016** May 1;310(10): F958-71.
6. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; **2004**-. PubChem Compound Summary for CID 3440, Furosemide; **2025** Sept. 12.
7. Hedaya MA. Bumetanide. *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; **2023**.
8. Brater DC. Diuretic therapy. *N Engl J Med*. **1998**;339(6):387-95.
9. Lytle C, Xu JC, Biemesderfer D, Forbush B 3rd. Distribution and diversity of Na-K-Cl cotransport proteins: a study with monoclonal antibodies. *Am J Physiol*. 1995;269(6 Pt 1):C1496-505.
10. Kramp RA, DiPette DJ, Gavras H. Clinical pharmacology of bumetanide. *Clin Pharmacol Ther*. **1982**;32(2):221-7.
11. Lant AF, Wilson GM. A comparison of bumetanide and furosemide. *Br Med J*. **1970**;4(5734):331-3.
12. Russell JM. Sodium-potassium-chloride cotransport. *Physiol Rev*. **2000**;80(1):211-76.
13. Lemonnier E, et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. *Transl Psychiatry*. **2012**;2(12): e202.

14. Löscher W, Kaila K. CNS pharmacology of bumetanide: from epilepsy to autism. *Pharmacol Ther*. **2022**; 230:107963.
15. Hedaya MA. *Bumetanide*. *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; **2023** [cited **2025** Sep 13].
16. Brater DC. Diuretic therapy. *N Engl J Med*. **1998** Aug 6;339(6):387-95.
17. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th Edition.
18. Brunton ll. Goodman & Gilman's manual of pharmacology and Therapeutics, 2nd Edition
19. Sweetman SC (ed). Martindale: The Complete Drug Reference, Pharmaceutical Press.
20. Katzung BG. Basic & Clinical Pharmacology, 15th Edition.
21. Mullens W, et al. Diuretic therapy in heart failure: current approaches and practical considerations. *J Am Coll Cardiol*. **2020**;75(3):233-245
22. Brater DC. Diuretic therapy. *N Engl J Med*. **1998**;339(6):387
23. Hedaya MA. Bumetanide. *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; **2023**.
24. Choudhary P, Kumar A. Analytical methods for loop diuretics: Bumetanide. *J Anal Pharm Res*. **2016**;5(1):1-8.
25. Bao-qiang R. "Determination of Bumetanide tablets by HPLC". *Strait Pharmaceutical Journal* 1 (**2006**): 77-78.
26. Dong-ming P., et al. "Determination of Bumetanide for injection by HPLC". *Chinese Journal of Modern Applied Pharmacy* 5(**2006**):404-406
27. Sanz NV., et al. "Determination and characterization of diuretics in human urine by liquid chromatography coupled to pneumatically assisted electrospray ionization mass spectrometry". *Journal of Mass Spectrometry* 36.6 (**2001**): 1-18.
28. Deventer K., et al. "Simultaneous determination of beta-blocking agents and diuretics in doping analysis by liquid chromatography/mass spectrometry with scan-to-scan polarity switching". Rapid Communication in Mass Spectrometry 19(**2005**): 90-98.
29. Seethi R., et al. "Development and validation of RP-HPLC for estimation of Bumetanide in tablet formulation". *Indian Journal of Field Veterinarians* 9.4 (**2014**): 46-53.
30. indian Pharmacopoeia Commission. Indian Pharmacopoeia 2018 – Furosemide monograph.
31. British Pharmacopoeia Commission. British Pharmacopoeia Online – Furosemide monograph.
32. European Directorate for the Quality of Medicines. European Pharmacopoeia 10.0. Furosemide monograph.
33. United States Pharmacopeia (USP 44–NF 39). Furosemide monograph.